Dyadic International, Inc. (DYAI): Price and Financial Metrics
DYAI Price/Volume Stats
|Current price||$1.90||52-week high||$2.40|
|Prev. close||$1.92||52-week low||$1.12|
|Day high||$1.90||Avg. volume||29,052|
|50-day MA||$1.85||Dividend yield||N/A|
|200-day MA||$1.75||Market Cap||54.74M|
DYAI Stock Price Chart Interactive Chart >
DYAI Stock Summary
- For DYAI, its debt to operating expenses ratio is greater than that reported by just 0.33% of US equities we're observing.
- DYAI's price/sales ratio is 16.76; that's higher than the P/S ratio of 93.99% of US stocks.
- Revenue growth over the past 12 months for DYADIC INTERNATIONAL INC comes in at 48.65%, a number that bests 88.78% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to DYADIC INTERNATIONAL INC, a group of peers worth examining would be NTRA, WISH, KLTR, BLZE, and NTNX.
- DYAI's SEC filings can be seen here. And to visit DYADIC INTERNATIONAL INC's official web site, go to www.dyadic.com.
DYAI Valuation Summary
- In comparison to the median Healthcare stock, DYAI's price/sales ratio is 317.5% higher, now standing at 16.7.
- Over the past 54 months, DYAI's price/earnings ratio has gone up 8.5.
Below are key valuation metrics over time for DYAI.
DYAI's Quality FactorsThe “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
- DYAI has a Quality Grade of D, ranking ahead of 6.48% of graded US stocks.
- DYAI's asset turnover comes in at 0.074 -- ranking 281st of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows DYAI's key quality metrics over time.
|Period||Asset Turnover||Gross Margin||ROIC|
Dyadic International, Inc. (DYAI) Company Bio
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd., as well as with the Israel Institute for Biological Research; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; research collaboration with Sanofi-Aventis Deutschland GmbH; research and commercialization collaboration with Serum Institute of India Pvt.; and nonexclusive research collaboration with WuXi Biologics. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
DYAI Latest News Stream
|Loading, please wait...|
DYAI Latest Social Stream
View Full DYAI Social Stream
Latest DYAI News From Around the Web
Below are the latest news stories about DYADIC INTERNATIONAL INC that investors may wish to consider to help them evaluate DYAI as an investment opportunity.
JUPITER, Fla., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that its management will be presenti
Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells
JUPITER, Fla. and PARIS, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI) and bYoRNA SAS ("bYoRNA") today announced that they entered into a development and commercialization agreement to work on disruptive bioproduction technologies that will help exploit the therapeutic potential of messenger RNA ("mRNA"). Dyadic is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduct
Dyadic Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using Dapibus™
Dyadic to receive upfront payment of $0.6 million for product development and licensing its Dapibus™ platform, in addition to potential success fees, milestones, and royalties. JUPITER, Fla., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet needs for effective, afford
JUPITER, Fla., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that Joseph Hazelton, Chief Business
By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT Second Quarter 2023 Operational & Financial Results Dyadic International Inc. (NASDAQ:DYAI) provided 2Q:23 operational and financial results in a press release on August 9, 2023, filed its Form 10-Q with the SEC and held a conference call with investors. 1 Dyadic announced several new collaborations and expanded
DYAI Price Returns